Achaogen (AKAO) is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics.

On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The first study, a Phase 3 trial of plazomicin for the treatment of patients with cUTI and acute pyelonephritis (“AP”), entitled EPIC (Evaluating Plazomicin In cUTI), is expected to serve as a single pivotal study supporting a new drug application (“NDA”) for plazomicin in the United States. The Phase 3 EPIC trial is a randomized, double blind, active controlled study in patients with cUTI and AP and allowed broad enrollment of patients with gram-negative infections. The company reached agreement with the U.S. Food and Drug Administration (“FDA”) that this trial comparing plazomicin to meropenem with a 15% non-inferiority margin is acceptable as the single study required for potential approval. The first patient was enrolled in the Phase 3 EPIC trial in January 2016 and enrollment was closed in August 2016 with 609 patients.

In the EPIC trial, plazomicin successfully met or exceeded the objective of non-inferiority compared to meropenem for the FDA-specified primary efficacy endpoints, and achieved superiority for the primary efficacy endpoints specified by the European Medicines Agency (“EMA”). Results for the FDA pre-specified composite endpoint of clinical cure and microbiological eradication in the microbiological modified intent-to-treat (“mMITT”) population at Day 5 achieved statistical non-inferiority, and Test-of-Cure (Day ~17) achieved statistical superiority. Results for EMA-specified endpoints of microbiological eradication at the test-of-cure visit achieved statistical superiority in both the mMITT and microbiologically evaluable (“ME”) populations.

Plazomicin was generally well tolerated with no new safety concerns identified in the EPIC trial. As previously disclosed, total treatment emergent adverse events (“TEAEs”) related to renal function were reported in 3.6% and 1.3% of patients in the plazomicin and meropenem groups, respectively. TEAEs related to cochlear or vestibular function were reported in a single patient in each of the plazomicin and meropenem treatment groups. Both events were considered mild and resolved completely.

The second study, its Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) trial was a resistant pathogen trial designed to evaluate the efficacy and safety of plazomicin in patients with serious bacterial infections due to CRE. The company closed enrollment in the CARE study in August 2016 with 69 patients, comprised of 39 patients enrolled in Cohort 1, comparing plazomicin to colistin-based therapy in patients with bloodstream infections or pneumonia due to CRE, and 30 patients in Cohort 2, a single arm cohort of plazomicin treatment in patients with serious infections due to CRE. In Cohort 1 of the CARE trial, a lower rate of mortality or serious disease-related complications was observed for plazomicin compared with colistin therapy.

The safety profile of plazomicin was favorable to that of colistin in critically ill patients in the CARE trial. As previously disclosed, study drug-related TEAEs related to renal function were reported in 16.7% and 38.1% of patients in the plazomicin and colistin groups, respectively. No TEAEs related to cochlear or vestibular function were reported in either group. However, due to the clinical status of patients enrolled in the trial who were frequently ventilated and unconscious, planned assessments of hearing and tinnitus were not possible for many of the patients.

The company plan to submit an NDA, which will include data from both the EPIC and CARE Phase 3 clinical trials, to the FDA in the second half of 2017, with a planned commercial launch of plazomicin in the United States in 2018, if its NDA is approved. The company also plan to submit a Marketing Authorization Application to the EMA for plazomicin in 2018.

On May 23, 2017, the company announced that, based on the results of the CARE study, the FDA granted Breakthrough Therapy designation for plazomicin for the treatment of bloodstream infections caused by certain Enterobacteriaceae, Klebsiella pneumoniae and Enterobacter aerogenes. Breakthrough Therapy designation is granted by the FDA to treat a serious condition and where preliminary clinical evidence demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapy. Breakthrough Therapy is intended to expedite the development and review of new therapies to treat such conditions. In 2012, the FDA granted fast-track designation for the development and regulatory review of plazomicin to treat serious and life-threatening CRE infections. In 2014, plazomicin received Qualified Infectious Disease Product (“QIDP”) designation from the FDA. The QIDP designation was created by the Generating Antibiotic Incentives Now (“GAIN”) Act, which was part of the FDA Safety and Innovation Act and provides certain incentives for the development of new antibiotics, including priority review and an additional five years of market exclusivity. Achaogen has global commercialization rights to plazomicin, which has patent protection in the United States estimated from 2030 to 2032.

The company recently announced its orally-available antibacterial candidate, C-Scape, a combination of an approved β-lactam and an approved β-lactamase inhibitor. The company believe that C-Scape has the potential to rapidly address a serious unmet need for an effective oral treatment for patients with cUTI, including AP, caused by ESBL-producing Enterobacteriaceae. The company began a Phase 1 study in the second quarter of 2017. In the event the Phase 1 trial is successful, the company intend to initiate a single pivotal Phase 3 study in patients with cUTI, including AP, who are suitable for treatment with oral antibiotics, by the first half of 2018. The company also have a program to discover and develop small molecule inhibitors of LpxC (an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria), which could be ready to file an investigational new drug application (“IND”) as early as 2018. The company's LpxC program is funded in part with an award from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) of $3.2 million, with potential funding of up to $11.4 million, and a contract from the National Institute of Allergy and Infectious Diseases for up to $5.3 million. The company's therapeutic antibody program utilizes a built-for-purpose discovery platform to identify and develop monoclonal antibodies for the treatment of MDR bacterial infections and other significant unmet medical needs. To further support that program, the company entered into a research agreement with the Bill & Melinda Gates Foundation (the “Gates Foundation”) to discover drug candidates against gram-negative bacterial pathogens intended to prevent neonatal sepsis (the “Grant Agreement”). Pursuant to the Grant Agreement, the Gates Foundation awarded up to $10.5 million in grant funding over a three-year research term. Achaogen has other programs in early stages of research targeting MDR gram-negative bacterial infections.

Since its inception, Achaogen has financed its operations with the proceeds from its initial public offering (“IPO”) of its common stock, proceeds from the underwritten public offering of its common stock, proceeds from sales of its common stock through the use of its at-the-market (“ATM”) equity offering program, funding under its contracts with a non-profit foundation and government agencies, private placements of its equity securities and certain debt-related financing arrangements.

The company's plazomicin program is funded in part with a contract from BARDA. The company's other programs are currently funded primarily with company funds, although, in 2015, the company received a contract from the National Institute of Allergy and Infectious Diseases (“NIAID”) that has total committed funding of $5.3 million. Historically, its preclinical programs have received funding support from organizations in addition to the National Institutes of Health, such as the U.S. Department of Defense and The Wellcome Trust, a global charitable foundation. The company intend to continue to seek further collaborations with government agencies, non-profit foundations, and other research and development funding organizations to support its discovery efforts and advance the product candidates in its pipeline.

On March 17, 2014, the company completed its IPO of common stock. The company sold 6,900,000 shares of its common stock, which included 900,000 shares issued as a result of the underwriters exercising their over-allotment option in full. The company received cash proceeds of approximately $73.9 million from the IPO, net of underwriting commissions and related expenses.

On April 7, 2015, the company entered into the Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), pursuant to which the company may issue and sell shares of its common stock having aggregate sales proceeds of up to $30.0 million from time to time through an ATM equity offering program under which Cowen acts as sales agent. As of June 30, 2017, the company had sold 1,105,549 shares under the Sales Agreement at an average price of $4.82 per share and the company received aggregate cash proceeds of $5.1 million, after deducting the sales commissions and offering expenses.

On August 5, 2015, the company entered into a loan and security agreement with Solar Capital Ltd., pursuant to which Solar Capital Ltd. agreed to make available to it term loans with an aggregate principal amount of up to $25.0 million, $15.0 million of which was provided to it on August 5, 2015 and $10.0 million of which was provided to it on June 20, 2016.

On May 26, 2016, BARDA exercised an additional option ("Option 3") under its existing contract, and the company were awarded an additional $20.0 million in contract funding. Option 3 also includes a no-cost extension of the period of performance for Option 1 to September 20, 2016, under the contract to support its Phase 3 EPIC trial of plazomicin. The funding from Option 3 is focused on the Phase 3 pivotal clinical trial of plazomicin, the EPIC study, in cUTI. In April 2017, BARDA modified Option 1 to allow for an additional $0.5 million of contract funding. This brings the total committed funding under the contract to $124.3 million.

On June 3, 2016, the company sold 7,999,996 shares of common stock and warrants to purchase 1,999,999 shares of common stock pursuant to a Securities Purchase Agreement (“Purchase Agreement”) for aggregate gross proceeds of $25.4 million and aggregate net proceeds of $25.1 million, after deducting the issuance costs, in a private placement financing transaction (the "Private Placement"). The warrants have an exercise price of $3.66 and are exercisable up to five years from the date of issuance.

On December 19, 2016, the company completed an underwritten public offering of common stock, which resulted in the sale of 7,475,000 shares, at a price of $13.50 per share to the public, including the full exercise of the underwriters’ option to purchase an additional 975,000 shares of common stock. The company received net proceeds from the offering of $94.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses.

On May 4, 2017, the company entered into the Grant Agreement with the Gates Foundation and were awarded up to approximately $10.5 million in grant funding over a three-year research term, of which approximately $3.2 million of committed funding was received in May 2017 (the “Advance Funds”). Concurrently with the Grant Agreement, the company entered into a Common Stock Purchase Agreement with the Gates Foundation, pursuant to which the company agreed to sell 407,331 shares of its contingently redeemable common stock to the Gates Foundation in a private placement at a purchase price per share equal to $24.55, for gross proceeds to it of $10.0 million (“Gates Investment”). In connection with the Grant Agreement and Gates Investment, the company entered into a strategic relationship with the Gates Foundation (the “Letter Agreement”). Under the terms of the Letter Agreement, the Gates Investment and Advanced Funds may only be used to conduct mutually agreed upon work, including the scale up of its antibody platform technology to launch a product intended to prevent neonatal sepsis (the “NSP”). Pursuant to the Letter Agreement, the company agreed to make the NSP available and accessible in certain developing countries and to grant the Gates Foundation a non-exclusive license to commercialize selected drug candidates in certain developing countries, which may only be exercised in the event of certain defaults as described in the Letter Agreement (the “Global Access Commitments”). The Global Access Commitments will continue in effect until the earlier of 25 years from the closing of the Gates Investment or 7 years following the termination of all funding provided by the Gates Foundation; provided, that the Global Access Commitments will continue for any products or services developed with funding provided by the Gates Foundation which continue to be developed or available in certain developing countries.

On May 31, 2017, the company completed an underwritten public offering of 5,750,000 shares of its common stock at a price to the public of $22.50 per share, including the closing of the full exercise of the underwriters’ option to purchase an additional 750,000 shares of common stock on June 9, 2017. The company received net proceeds from the offering of $121.2 million, after deducting the underwriting discounts and commissions and offering expenses.

Achaogen has never been profitable and have incurred net losses in each year since the commencement of its operations. Substantially all of its net losses have resulted from costs incurred in connection with its research and development programs and associated general and administrative costs. The company expect to incur substantial losses from operations in the foreseeable future as the company advance plazomicin and other product candidates through preclinical and clinical development, seek regulatory approval, and prepare for, if approved, commercialization. Management expects that, based on its current operating plans, its existing cash, cash equivalents and short-term investments, will be sufficient to fund its current planned operations for at least the next twelve months from the issuance of these financial statements. The company will be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources to invest in the commercial launch of plazomicin and continued progress with its research and development efforts. Adequate additional financing may not be available to it on acceptable terms, or at all. The company's failure to raise capital as and when needed would have a negative impact on its financial condition and its ability to pursue its business strategy. The company perform all of its manufacturing in conjunction with third parties. Additionally, the company currently utilize third-party clinical research organizations (“CROs”) to carry out its clinical development and are building a sales organization. The company will need substantial additional funding to support its operating activities and adequate funding may not be available to it on acceptable terms, or at all.

Research and Development Pipeline

The following table summarizes the status of plazomicin and its other preclinical and research programs:



Created by Wilton on 2019/09/01 16:04

Become a Contributor

If you follow a company closely and would like to share your knowledge, we would love your contributions. Register Now and start editing!

Tag Cloud

  1. AU:DTL
  2. AU:PNC
  3. AU:SSR
  4. Bangladesh
  5. BD:ACI
  11. BD:GP
  16. BD:RBBL
  18. BD:ROBI
  22. CA:ABX
  23. CA:AC
  24. CA:AEM
  25. CA:AFI
  26. CA:AGI
  27. CA:BAM.A
  28. CA:BCE
  29. CA:BLDP
  30. CA:BMO
  31. CA:BNS
  32. CA:BTO
  33. CA:CCO
  34. CA:CM
  35. CA:CNQ
  36. CA:CNR.TO
  37. CA:CP
  38. CA:CSU
  39. CA:CU
  40. CA:CVE
  41. CA:EMA
  42. CA:ENB
  43. CA:FFH
  44. CA:FM
  45. CA:FSV
  46. CA:FTS
  47. CA:GFL
  48. CA:GIB
  49. CA:GWO
  50. CA:IFC
  51. CA:IMO
  52. CA:K
  53. CA:LULU
  54. CA:MFC
  55. CA:MG
  56. CA:MRU
  57. CA:MX
  58. CA:NA
  59. CA:NG
  60. CA:NTR
  61. CA:OTEX
  62. CA:POW
  63. CA:PVG
  64. CA:QSR
  65. CA:RBA
  66. CA:RCI.A
  67. CA:RY
  68. CA:SHOP
  69. CA:SJR.B
  70. CA:SLF
  71. CA:SSRM
  72. CA:SU
  73. CA:T
  74. CA:TA
  75. CA:TARD
  76. CA:TD
  77. CA:TECK
  78. CA:TFII
  79. CA:TRI
  80. CA:TRP
  81. CA:WEED
  82. CA:X
  83. CA:YRI
  84. Canada
  85. CH:ALSN
  86. CH:NESN
  87. CIPLA
  88. DE:TIMA
  89. EU:CCAP
  90. EU:HHFA
  91. FR:CEN
  92. FR:HCO
  93. GB:AAL
  94. GB:ABDN
  95. GB:ABF
  96. GB:ADM
  97. GB:AHT
  98. GB:ANTO
  99. GB:AUTO
  100. GB:AUY
  101. GB:AV
  102. GB:AVST
  103. GB:AVV
  104. GB:AZN
  105. GB:BA
  106. GB:BARC
  107. GB:BATS
  108. GB:BDEV
  109. GB:BHP
  110. GB:BME
  111. GB:BP
  112. GB:CCH
  113. GB:CPG
  114. GB:CTO
  115. GB:DARK
  116. GB:DGE
  117. GB:FERG
  118. GB:GLEN
  119. GB:HL
  120. GB:HSBA
  121. GB:IHG
  122. GB:III
  123. GB:IMB
  124. GB:INCH
  125. GB:NWG
  126. GB:NXR
  127. GB:OCDO
  128. GB:REL
  129. GB:RKT
  130. GB:SGE
  131. GB:SGRO
  132. GB:SKG
  133. GB:SMIN
  134. GB:SN
  135. GB:STAN
  136. GB:STJ
  137. GB:ULVR
  138. Great Britain
  139. HK:0995
  140. HK:1052
  141. HK:107
  142. HK:189
  143. HK:548
  144. HK:819
  145. HK:995
  146. IN:3MINDIA
  149. IN:CIPLA
  153. IN:IDEA
  155. IN:LICI
  156. IN:LUPIN
  157. IN:LUPINE
  158. IN:MFSL
  159. IN:MOFSL
  164. IN:NBCC
  166. IN:NIACL
  167. IN:NMDC
  169. IN:OFSS
  171. IN:PAYTM
  172. IN:PEL
  174. IN:PFIZER
  175. IN:PGHH
  177. IN:PIIND
  178. IN:PNB
  181. IN:QUESS
  183. IN:RELAXO
  184. IN:SAIL
  185. IN:SANOFI
  188. IN:SRF
  191. IN:TECHM
  192. IN:TITAN
  195. IN:TRENT
  197. IN:UBL
  200. IN:UPL
  201. IN:VBL
  203. IN:ZEEL
  204. India
  205. Ireland
  206. JP:1070
  207. JP:2654
  208. JP:4220
  209. JP:4734
  210. JP:6916
  211. SG:BCY
  212. SG:F13
  213. UK:IHG
  214. US:AABA
  215. US:AAOI
  216. US:AAPL
  217. US:AAUKF
  218. US:ABEO
  219. US:ABUS
  220. US:ACAD
  221. US:ACAN
  222. US:ACBFF
  223. US:ACDVF
  224. US:ACHN
  225. US:ACIA
  226. US:ACRX
  227. US:ADAP
  228. US:ADMP
  229. US:ADMS
  230. US:ADXS
  231. US:AEM
  232. US:AEZS
  233. US:AFMD
  234. US:AGEN
  235. US:AGI
  236. US:AGRX
  237. US:AGTK
  238. US:AKAO
  239. US:ALDR
  240. US:ALIM
  241. US:ALQA
  242. US:AMC
  243. US:AMD
  244. US:AMDA
  245. US:AMIGF
  246. US:AMMJ
  247. US:AMN
  248. US:AMPE
  249. US:AMRN
  250. US:AMRS
  251. US:AMZN
  252. US:ANCUF
  253. US:ANFGF
  254. US:ANLDF
  255. US:ANTH
  256. US:ANY
  257. US:APHQF
  258. US:AQMS
  259. US:AQSZF
  260. US:ARDX
  261. US:ARGS
  262. US:ARLZ
  263. US:ARNA
  264. US:ARRY
  265. US:ARWR
  266. US:ASBFF
  267. US:ASHTF
  268. US:ATDRY
  269. US:ATHX
  270. US:ATNM
  271. US:ATOS
  272. US:ATRS
  273. US:AUPH
  274. US:AUY
  275. US:AVASF
  276. US:AVEO
  277. US:AVEVF
  278. US:AVGR
  279. US:AVIR
  280. US:AVP
  281. US:AVVIY
  282. US:AVXL
  283. US:AXON
  284. US:AXSM
  285. US:AZN
  286. US:BABA
  287. US:BAC
  288. US:BAESF
  289. US:BAM
  290. US:BBRY
  291. US:BCE
  292. US:BCOR
  293. US:BCS
  294. US:BHC
  295. US:BHP
  296. US:BIOA
  297. US:BIOC
  298. US:BLCM
  299. US:BLDP
  300. US:BLEVF
  301. US:BLOZF
  302. US:BLPH
  303. US:BLRX
  304. US:BMO
  305. US:BMRPF
  306. US:BNS
  307. US:BP
  308. US:BPMX
  309. US:BSTG
  310. US:BTDPF
  311. US:BTE
  312. US:BTG
  313. US:BTI
  314. US:BW
  315. US:BZUN
  316. US:CALA
  317. US:CANN
  318. US:CAPR
  319. US:CARA
  320. US:CASC
  321. US:CATB
  322. US:CBDS
  323. US:CCJ
  324. US:CEI
  325. US:CERC
  326. US:CERU
  327. US:CHK
  328. US:CIE
  329. US:CLDX
  330. US:CLF
  331. US:CLOV
  332. US:CLSN
  333. US:CLVS
  334. US:CM
  335. US:CMPGF
  336. US:CNAB
  337. US:CNAT
  338. US:CNBX
  339. US:CNI
  340. US:CNQ
  341. US:CNSWF
  342. US:CORT
  343. US:CP
  344. US:CPRX
  345. US:CRBP
  346. US:CRIS
  347. US:CRMD
  348. US:CTRV
  349. US:CU
  350. US:CUR
  351. US:CVE
  352. US:CVSI
  353. US:CYCC
  354. US:CYTR
  355. US:CYTX
  356. US:DCTH
  357. US:DEPO
  358. US:DGEAF
  359. US:DMPI
  360. US:DRKTF
  361. US:DRYS
  362. US:DVAX
  363. US:DXTR
  364. US:DYLLF
  365. US:EARS
  366. US:ECYT
  367. US:EDIT
  368. US:EGLT
  369. US:EKSO
  370. US:ELVT
  371. US:ENB
  372. US:ENDP
  373. US:ENRT
  374. US:ETRM
  375. US:EVC
  376. US:EXEL
  377. US:FATE
  378. US:FB
  379. US:FERG
  380. US:FINL
  381. US:FIT
  382. US:FLXN
  383. US:FOLD
  384. US:FQVLF
  385. US:FRFHF
  386. US:FSV
  387. US:FTR
  388. US:FTS
  389. US:FVE
  390. US:FWDG
  391. US:GALE
  392. US:GALT
  393. US:GBHPF
  394. US:GBT
  395. US:GERN
  396. US:GFL
  397. US:GIB
  398. US:GILD
  399. US:GLDFF
  400. US:GLEN
  401. US:GLYC
  402. US:GME
  403. US:GNCA
  404. US:GNMX
  405. US:GOLD
  406. US:GPRO
  407. US:GSAT
  408. US:GVXXF
  409. US:GWLIFU
  410. US:HLTH
  411. US:HMNY
  412. US:HRGLF
  413. US:HRTX
  414. US:HSBA
  415. US:HTGM
  416. US:HTZ
  417. US:HUSA
  418. US:ICPT
  419. US:IDRA
  420. US:IDXG
  421. US:IFCZF
  422. US:IHG
  423. US:IMBBF
  424. US:IMGN
  425. US:IMMU
  426. US:IMNP
  427. US:IMO
  428. US:IMUC
  429. US:INFI
  430. US:INPX
  431. US:INSM
  432. US:INVA
  433. US:ITEK
  434. US:IVITF
  435. US:JD
  436. US:JOBS
  437. US:JVA
  438. US:KAYS
  439. US:KEM
  440. US:KERX
  441. US:KGC
  442. US:KTOS
  443. US:KTOV
  444. US:LKM
  445. US:LODE
  446. US:LPCN
  447. US:LULU
  448. US:LXRP
  449. US:MACK
  450. US:MARA
  451. US:MBOT
  452. US:MBRX
  453. US:MDCL
  454. US:MDCO
  455. US:MEET
  456. US:MEIP
  457. US:MEOH
  458. US:MFC
  459. US:MGA
  460. US:MGWFF
  461. US:MNKD
  462. US:MOMO
  463. US:MQPXF
  464. US:MRNS
  465. US:MRTX
  466. US:MSFT
  467. US:MTRAFU
  468. US:MU
  469. US:MVIS
  470. US:MZOR
  471. US:NAK
  472. US:NBEV
  473. US:NBRV
  474. US:NEOS
  475. US:NG
  476. US:NH
  477. US:NLNK
  478. US:NMUS
  479. US:NTIOF
  480. US:NTNX
  481. US:NTR
  482. US:NVAX
  483. US:NVCN
  484. US:NVDA
  485. US:NVRO
  486. US:NWBO
  487. US:NWG
  488. US:NXTTF
  489. US:NYMX
  490. US:OCDGF
  491. US:OCLR
  492. US:OCUL
  493. US:OGRMF
  494. US:OMER
  495. US:ONCS
  496. US:ONTX
  497. US:ONVO
  498. US:OPGN
  499. US:OPHT
  500. US:OPK
  501. US:OPTT
  502. US:OTEX
  503. US:OTIC
  504. US:P
  505. US:PANXF
  506. US:PBYI
  507. US:PETS
  508. US:PETX
  509. US:PGNX
  510. US:PHOT
  511. US:PIRS
  512. US:PLSE
  513. US:PLUG
  514. US:PLX
  515. US:PRTO
  516. US:PSDV
  517. US:PTI
  518. US:PTN
  519. US:PTX
  520. US:PUFXF
  521. US:PULM
  522. US:PVG
  523. US:QRSRF
  524. US:QSR
  525. US:RAD
  526. US:RBA
  527. US:RBGPF
  528. US:RCI
  529. US:RCKT
  530. US:RDHL
  531. US:RDUS
  532. US:RELX
  533. US:REPH
  534. US:RGLS
  535. US:RIGL
  536. US:RNN
  537. US:RNVA
  538. US:ROX
  539. US:RSSFF
  540. US:RTTR
  541. US:RY
  542. US:SCYX
  543. US:SDRL
  544. US:SEGXF
  545. US:SENS
  546. US:SESN
  547. US:SGBY
  548. US:SGGEF
  549. US:SGMO
  550. US:SGYP
  551. US:SHOP
  552. US:SJR
  553. US:SKLN
  554. US:SLF
  555. US:SLFPF
  556. US:SMFTF
  557. US:SMGKF
  558. US:SNAP
  559. US:SNN
  560. US:SPHS
  561. US:SPLIF
  562. US:SPRWF
  563. US:SQ
  564. US:SRNA
  565. US:SRNE
  566. US:SRRA
  567. US:SSRM
  568. US:STJPF
  569. US:STLY
  570. US:STML
  571. US:STMP
  572. US:STRRF
  573. US:SU
  574. US:SWN
  575. US:SYN
  576. US:TAC
  577. US:TBQBF
  578. US:TD
  579. US:TECK
  580. US:TENX
  581. US:TEVA
  582. US:TFII
  583. US:TGOPF
  584. US:TGTX
  585. US:THCBF
  586. US:TK
  587. US:TMXXF
  588. US:TNDM
  589. US:TOP
  590. US:TRI
  591. US:TROV
  592. US:TRP
  593. US:TRTC
  594. US:TRVN
  595. US:TRXC
  596. US:TSG
  597. US:TSLA
  598. US:TTM
  599. US:TTNP
  600. US:TTNQY
  601. US:TU
  602. US:TVTY
  603. US:TWTR
  604. US:TXMD
  605. US:UBQU
  606. US:UNXL
  607. US:VAPE
  608. US:VBLT
  609. US:VCEL
  610. US:VDQSF
  611. US:VPCO
  612. US:VSTM
  613. US:WIT
  614. US:WLDFF
  615. US:WLL
  616. US:WMIH
  617. US:WMT
  618. US:XGTI
  619. US:XON
  620. US:XTNT
  621. US:XXII
  622. US:ZGNX
  623. US:ZSAN
  624. US:ZYNE
This site is funded and maintained by Fintel.io